Allergan (NYSE:AGN)‘s stock had its “buy” rating restated by Deutsche Bank in a report released on Tuesday. They currently have a $215.00 target price on the stock. Deutsche Bank’s target price points to a potential upside of 23.57% from the company’s current price.

Several other research analysts also recently commented on the stock. Argus downgraded shares of Allergan from a “buy” rating to a “hold” rating and cut their price objective for the stock from $256.80 to $160.07 in a report on Thursday, December 7th. JPMorgan Chase & Co. set a $275.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Sunday, October 22nd. Morgan Stanley downgraded shares of Allergan from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $284.00 to $228.00 in a report on Wednesday, September 20th. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Vetr downgraded shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price objective for the company. in a report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $227.22.

Allergan (NYSE:AGN) traded down $1.66 during trading on Tuesday, hitting $173.99. 2,118,800 shares of the stock were exchanged, compared to its average volume of 3,020,000. Allergan has a 1 year low of $160.07 and a 1 year high of $256.80. The company has a market cap of $58,420.00, a P/E ratio of -7.70, a P/E/G ratio of 1.18 and a beta of 1.11. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.

Allergan (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.32 EPS. research analysts expect that Allergan will post 16.27 earnings per share for the current fiscal year.

Allergan announced that its board has initiated a stock buyback program on Monday, September 25th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

In other news, Director Chris W. Bodine bought 3,030 shares of the stock in a transaction on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, for a total transaction of $499,253.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider William Meury sold 11,807 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders acquired a total of 17,630 shares of company stock worth $2,890,057 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AGN. Beach Investment Management LLC. raised its position in shares of Allergan by 845.2% during the 2nd quarter. Beach Investment Management LLC. now owns 93,195 shares of the company’s stock valued at $22,655,000 after buying an additional 83,335 shares in the last quarter. Peddock Capital Advisors LLC purchased a new stake in shares of Allergan during the 2nd quarter valued at $1,718,000. iAB Financial Bank raised its position in shares of Allergan by 77.3% during the 2nd quarter. iAB Financial Bank now owns 1,775 shares of the company’s stock valued at $431,000 after buying an additional 774 shares in the last quarter. Graybill Bartz & Assoc Ltd. raised its position in shares of Allergan by 1.4% during the 2nd quarter. Graybill Bartz & Assoc Ltd. now owns 17,886 shares of the company’s stock valued at $4,348,000 after buying an additional 251 shares in the last quarter. Finally, Boston Private Wealth LLC raised its position in shares of Allergan by 7.3% during the 2nd quarter. Boston Private Wealth LLC now owns 92,663 shares of the company’s stock valued at $22,525,000 after buying an additional 6,344 shares in the last quarter. Institutional investors and hedge funds own 81.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/allergans-agn-buy-rating-reiterated-at-deutsche-bank/1802006.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.